Dr Reddys Laboratories (RDY) Cost of Revenue (2009 - 2026)
Dr Reddys Laboratories (RDY) posted Cost of Revenue of $455.94 million for the quarter ended Jun 30, 2026, up 6.0% from $430.29 million a year earlier and up 0.5% from the prior quarter.
Dr Reddys Laboratories (RDY) Cost of Revenue (2009 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Cost of Revenue at Dr Reddys Laboratories was $1.82 billion, up 9.6% year-over-year; for the year ended Mar 31, 2026, it came in at $1.69 billion, up 7.0% from the prior year.
- Annual Cost of Revenue has increased for three consecutive years, with a five-year compound annual growth rate of 7.4% (years ended Mar 2021 to Mar 2026).
- In prior years, Dr Reddys Laboratories' Cost of Revenue was $1.58 billion in the year ended Mar 31, 2025 (+14.0%), $1.39 billion in the year ended Mar 31, 2024 (+7.0%), $1.3 billion in the year ended Mar 31, 2023 (-2.2%) and $1.33 billion in the year ended Mar 31, 2022 (+11.8%).
- Quarterly Cost of Revenue has run from a low of $324 million in the quarter ended Sep 30, 2021 to a high of $457.57 million in the quarter ended Sep 30, 2025 over five years.
- On a year-over-year basis, Cost of Revenue has increased in each of the last 13 quarters, with growth averaging 13.4% over the last eight quarters.
- The strongest year-over-year quarter for Cost of Revenue in the past five years was the quarter ended Mar 31, 2025, with growth of 23.5%; the weakest was the quarter ended Jun 30, 2022, with a decline of 6.3%.
- According to Business Quant data, Cost of Revenue for the three prior quarters was $453.66 million (quarter ended Mar 31, 2026), $454.37 million (quarter ended Dec 31, 2025) and $457.57 million (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 3.27 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 8.05 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 4.29 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 4.40 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.71 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.52 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.81 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 1.58 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.09 Bn |
| 10 | Dr Reddys Laboratories | 10.22 Bn | 9.41 Bn | 396.53 Mn | 455.94 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 455.94 Mn |
| Mar 31, 2026 | 453.66 Mn |
| Dec 31, 2025 | 454.37 Mn |
| Sep 30, 2025 | 457.57 Mn |
| Jun 30, 2025 | 430.29 Mn |
| Mar 31, 2025 | 436.48 Mn |
| Dec 31, 2024 | 409.01 Mn |
| Sep 30, 2024 | 386.75 Mn |
| Jun 30, 2024 | 364.22 Mn |
| Mar 31, 2024 | 353.38 Mn |
| Dec 31, 2023 | 359.64 Mn |
| Sep 30, 2023 | 343.97 Mn |
| Jun 30, 2023 | 342.00 Mn |
| Mar 31, 2023 | 335.00 Mn |
| Dec 31, 2022 | 329.00 Mn |
| Sep 30, 2022 | 336.00 Mn |
| Jun 30, 2022 | 339.10 Mn |
| Mar 31, 2022 | 340.79 Mn |
| Dec 31, 2021 | 338.00 Mn |
| Sep 30, 2021 | 324.00 Mn |
Dr Reddys Laboratories Cost of Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=RDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cost-of-revenue", "ticker": "RDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=RDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();